These findings suggested that the 22Rv1-CR-1 model may be useful for evaluating therapeutic strategies targeting mesothelin for aggressive PCa cells with EMP features or reduced prostate differentiation. The gene discussed is MSLN; the disease is posterior cortical atrophy.